{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Le Meur Y"],"funding":["Direction Générale de l'offre de Soins"],"pagination":["302"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10150461"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["<h4>Background</h4>Preventing ischemia‒reperfusion injury (IRI) is a major issue in kidney transplantation, particularly for transplant recipients receiving a kidney from extended criteria donors (ECD). The main consequence of IRI is delayed graft function (DGF). Hypoxia is one of the key factors in IRI, suggesting that the use of an oxygen carrier as an additive to preservation solution may be useful. In the OxyOp trial, we showed that the organs preserved using the oxygen carrier HEMO2life® displayed significantly less DGF. In the OxyOp2 trial, we aim to definitively test and quantify the efficacy of HEMO2life® for organ preservation in a large population of kidney grafts.<h4>Methods</h4>OxyOp2 is a prospective, multicenter, randomized, comparative, single-blinded, parallel-group study v"],"journal":["Trials"],"pubmed_title":["Evaluation of the efficacy of HEMO<sub>2</sub>life®, a marine OXYgen carrier for Organ Preservation (OxyOp2) in renal transplantation: study protocol for a multicenter randomized trial."],"pmcid":["PMC10150461"],"funding_grant_id":["PHRC national 2019"],"pubmed_authors":["Demini L","Merville P","Golbin L","Dantal J","Barrou B","Zal F","Le Meur Y","Nowak E","Kamar N","Badet L","Duveau A","Thierry A","Rerolle JP","Buchler M"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of the efficacy of HEMO<sub>2</sub>life®, a marine OXYgen carrier for Organ Preservation (OxyOp2) in renal transplantation: study protocol for a multicenter randomized trial.","description":"<h4>Background</h4>Preventing ischemia‒reperfusion injury (IRI) is a major issue in kidney transplantation, particularly for transplant recipients receiving a kidney from extended criteria donors (ECD). The main consequence of IRI is delayed graft function (DGF). Hypoxia is one of the key factors in IRI, suggesting that the use of an oxygen carrier as an additive to preservation solution may be useful. In the OxyOp trial, we showed that the organs preserved using the oxygen carrier HEMO2life® displayed significantly less DGF. In the OxyOp2 trial, we aim to definitively test and quantify the efficacy of HEMO2life® for organ preservation in a large population of kidney grafts.<h4>Methods</h4>OxyOp2 is a prospective, multicenter, randomized, comparative, single-blinded, parallel-group study v","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-22T02:29:49.033Z","creation":"2024-11-08T20:25:35.31Z"},"accession":"S-EPMC10150461","cross_references":{"pubmed":["37127632"],"doi":["10.1186/s13063-023-07302-3"]}}